Matthias Kloor is Deputy Director of the Department of Applied Tumor Biology, Institute of Pathology, at the Heidelberg University Hospital. His primary expertise is molecular pathogenesis and immune biology of microsatellite-unstable (MSI) tumors. Pioneering the field of MSI tumor biology, his research group identified recurrent mutational events crucial for MSI carcinogenesis leading to shared cancer neoantigens in Lynch syndrome tumors. This research guided the development of a first-in-man vaccine against a non-viral cancer designed specifically for Lynch syndrome patients, which became part of the Cancer Moonshot Program of the National Cancer Institute (NCI), USA, and is integrated in the CAP-IT program of the NCI.
At the EHTG 2024, Prof. Kloor is going to talk about immune-based approaches for cancer prevention and present the progress on research on vaccines in Lynch syndrome.